Fabry Disease: Renal Involvement Limited to Podocyte Pathology and Proteinuria in a Septuagenarian Cardiac Variant. Pathologic and Therapeutic Implications

American Journal of Kidney Diseases

Volumn 43, Issue 1, 2004, Pages 164-171

  Meehan, Shane M ^b   Junsanto, Tipsuda ^b   Rydel, James J ^b   Desnick, Robert J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cardiac variant; Fabry disease; Lysosomal storage disease; Podocyte; Proteinuria; Renal pathology; Ultrastructure; galactosidase A ( Gal A)

Indexed keywords

ALPHA GALACTOSIDASE; CREATININE; GLYCOSPHINGOLIPID;

AGED; ARTERIOSCLEROSIS; ARTICLE; BIOACCUMULATION; CASE REPORT; CELL ULTRASTRUCTURE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ASSAY; FABRY DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY TUBULE CELL; LEUKOCYTE; LYSOSOME; MALE; MESANGIUM CELL; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PODOCYTE; PROTEINURIA; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

EID: 0347989591     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.09.022     Document Type: Article

References (40)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163-1167, 1967
2. Klint JA: Fabry disease: α-Galactosidase deficiency. Science 167:1268-1269, 1970
3. Desnick RJ, Ioannou YA, Eng CM: α-Galactosidase A deficiency: Fabry disease, in Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease (ed 8). New York, NY, McGraw-Hill, 2001, pp 3733-3774
4. McNary W, Lowenstein L: A morphological study of the renal lesion in angiokeratoma corporis diffusum universale (Fabry's disease). J Urol 93:641, 1965
5. Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R: Renal pathologic lesions and functional alterations in a man with Fabry's disease. Am J Med 55:415-425, 1973
6. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH: Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation 54:818-825, 1976
7. Willard HF: The sex chromosome and X chromosome inactivation, in Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease (ed 8). New York, NY, McGraw-Hill, 2001, pp 1191-1212
8. Colley J, Miller D, Huntt M, Wallace H: The renal lesion in angiokeratoma corporis diffusum. Br Med J 1:1266-1268, 1958
9. Meroni M, Sessa A, Battini G, Tazzari S, Torri Tarelli L: Kidney involvement in Anderson-Fabry disease. Contrib Nephrol 122:178-184, 1997
10. Bernstein J, Churg J: Heritable metabolic diseases, in Jennette JC, Olson JL, Schwartz MM, Silva FG (eds): Heptinstall's Pathology of the Kidney. Philadelphia, PA, Lippincott-Raven, 1999, pp 1289-1292
11. Branton MH, Schiffmann R, Sabnis SG, et al: Natural history of Fabry renal disease: Influence of α-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122-138, 2002
12. Thurberg BL, Rennke H, Colvin RB, et al: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933-1946, 2002
13. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H: Angiokeratoma corporis diffusum-Fabry's disease. Helv Med Acta 34:67-83, 1967
14. Thadhani R, Wolf M, West ML, et al: Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249-255, 2002
15. Ojo A, Meier-Kriesche HU, Friedman G, et al: Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 69:2337-2339, 2000
16. Elleder M, Bradova V, Smid F, et al: Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417:449-455, 1990
17. von Scheidt W, Eng CM, Fitzmaurice TF, et al: An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324:395-399, 1991
18. Nagao Y, Nakashima H, Fukuhara Y, et al: Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of α-galactosidase A. Clin Genet 39:233-237, 1991
19. Nakao S, Takenaka T, Maeda M, et al: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333:288-293, 1995
20. Sachdev B, Takenaka T, Teraguchi H, et al: Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407-1411, 2002
21. Clarke JT, Knaack J, Crawhall JC, Wolfe LS: Ceramide trihexosidosis (Fabry's disease) without skin lesions. N Engl J Med 284:233-235, 1971
22. Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, Desnick RJ: Fabry disease: Thirty-five mutations in the α-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3:174-182, 1997
23. Ashton-Prolla P, Tong B, Astrin KH, Shabbeer J, Eng CM, Desnick RJ: 22 novel mutations in the α-galactosidase A gene and genotype/phenotype correlations including mild hemizygotes and severely affected heterozygotes. J Invest Med 48:227-235, 2000
24. Ishii S, Kase R, Sakuraba H, et al: Human α-galactosidase gene expression: Significance of two peptide regions encoded by exons 1-2 and 6. Biochim Biophys Acta 1204: 265-270, 1994
25. Sakuraba H, Oshima A, Fukuhara Y, et al: Identification of point mutations in the α-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 47:784-789, 1990
26. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W: Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes. α-Galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81:157-171, 1973
27. Kornreich R, Desnick RJ: Fabry disease: Detection of gene rearrangements in the human α-galactosidase A gene by multiplex PCR amplification. Hum Mutat 2:108-111, 1993
28. Ishii S, Sakuraba H, Suzuki Y: Point mutations in the upstream region of the α-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 89:29-32, 1992
29. Ishii S, Kase R, Sakuraba H, Suzuki Y: Characterization of a mutant α-galactosidase gene product for the lateonset cardiac form of Fabry disease. Biochem Biophys Res Commun 197:1585-1589, 1993
30. Kase R, Bierfreund U, Klein A, et al: Characterization of two α-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease. Biochim Biophys Acta 1501:227-235, 2000
31. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ: Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53:1186-1197, 1993
32. Topaloglu AK, Ashley GA, Tong B, et al: Twenty novel mutations in the α-galactosidase A gene causing Fabry disease. Mol Med 5:806-811, 1999
33. Ashley GA, Shabbeer J, Yasuda M, Eng CM, Desnick RJ: Fabry disease: Twenty novel α-galactosidase A mutations causing the classical phenotype. J Hum Genet 46:192-196, 2001
34. Altarescu GM, Goldfarb LG, Park KY, et al: Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 60:46-51, 2001
35. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R: Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13:223-235, 1978
36. Sheth KJ, Roth DA, Adams MB: Early renal failure in Fabry's disease. Am J Kidney Dis 2:651-654, 1983
37. Eng CM, Banikazemi M, Gordon R, et al: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711-722, 2001
38. Eng CM, Guffon N, Wilcox WR, et al: Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345:9-16, 2001
39. Schiffmann R, Kopp JB, Austin HA 3rd, et al: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285:2743-2749, 2001
40. De Schoenmakere G, Chauveau D, Grunfeld JP: Enzyme replacement therapy in Anderson-Fabry's disease: Beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18:33-35, 2003